Section Arrow
Quote
DFTX.NASDAQ
- Definium Therapeutics Inc
Quotes are at least 15-min delayed:2026/03/02 18:32 EST
After Hours
Last
 17.18
0 (0.00%)
Bid
17
Ask
17.75
High 17.59 
Low 17 
Volume 67.28K 
Regular Hours (Closed)
Last
 17.18
-0.28 (-1.60%)
Day High 
17.66 
Prev. Close
17.46 
1-M High
18.7 
Volume 
2.62M 
Bid
17
Ask
17.75
Day Low
16.7278 
Open
16.76 
1-M Low
15.615 
Market Cap 
1.72B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 17.12 
20-SMA 17.13 
50-SMA 15.6 
52-W High 18.7 
52-W Low 4.7 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.98/-2.26
Enterprise Value
1.74B
Balance Sheet
Book Value Per Share
1.33
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
IBRXImmunityBio10.44+0.64+6.53%-- 
After Hours 10.43 -0.01 -0.10%
QNCXQuince Therapeutics0.1-0.0201-16.74%-- 
After Hours 0.104 +0.004 +4.00%
OCULOcular Therapeutix10.98+2.035+22.75%-- 
After Hours 10.99 +0.01 +0.09%
QUREuniQure NV10.485-5.095-32.70%-- 
After Hours 10.32 -0.165 -1.57%
GERNGeron Corp1.555-0.125-7.44%-- 
After Hours 1.57 +0.015 +0.96%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial andoperational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.